Benign Prostatic Hyperplasia Surgical Treatment Market Report: Trends, Forecast and Competitive Analysis to 2031

Benign Prostatic Hyperplasia Surgical Treatment Market Trends and Forecast

The future of the global benign prostatic hyperplasia surgical treatment market looks promising with opportunities in the hospital, ambulatory surgery centers & clinic, and homecare setting markets. The global benign prostatic hyperplasia surgical treatment market is expected to grow with a CAGR of 5.2% from 2025 to 2031. The major drivers for this market are the rising geriatric male population, the growing awareness of treatment options, and the increase in prostate-related disorders.

• Lucintel forecasts that, within the type category, transurethral resection of the prostate is expected to witness the highest growth over the forecast period.

• Within the end use category, the homecare setting is expected to witness the highest growth.

• In terms of region, North America is expected to witness the highest growth over the forecast period. Gain valuable insights for your business decisions with our comprehensive 150+ page report. Sample figures with some insights are shown below.

Emerging Trends in the Benign Prostatic Hyperplasia Surgical Treatment Market

The benign prostatic hyperplasia surgical treatment market is experiencing a revolutionary era, fueled by a confluence of technological advancements, changing patient attitudes, and economic factors. The transition away from very invasive interventions towards less traumatic options is a prevailing trend, with improved patient experiences and lowered healthcare costs in prospect. These new directions represent an international consensus to enhance outcomes, streamline recovery, and broaden access to effective management of BPH. Recognizing these transitions is essential for the concerned stakeholders to steer the changing environment and leverage the opportunity for better gains to ultimately achieve for an immense population of patients.

• Minimally Invasive Surgical Therapies Dominance: The market is witnessing a strong penetration of MISTs, including prostatic urethral lift (PUL), water vapor thermal therapy (Reum), and prostatic artery embolization (PAE). These procedures have multiple advantages, including shorter hospital stays, less recovery time, less risk of sexual dysfunction, and, in many instances, can be done on an outpatient basis. This trend is motivated by patients need for less invasive treatment as well as more cost-effective and efficient treatments by healthcare providers, and as such, BPH management undergoes a paradigm shift.

• Technological Improvements in Laser Treatments: Laser treatments, most notably Holmium Laser Enucleation of the Prostate (Ho LEP), improve with enhanced instrumentation and techniques. More recent generations of lasers have better precision, shorter tissue removal times, and improved hemostasis, and are thus increasingly acceptable for all sizes of prostates. These improvements are also prompting the replacement of conventional TURP in bigger prostates, since Ho LEP provides similar efficacy with less morbidity and a reduced re-treatment rate, cementing its status as a gold standard.

• Emphasis on Office-Based Procedures: There is an increasing move towards designing and conducting BPH surgical procedures in an office setup instead of a hospital operating theater. This is extremely cost-effective, increases patient convenience, and eliminates the logistical hiccups that come with hospital-based procedures. Procedures such as Reum and Uro Lift are leading this movement, allowing treatment to be safely and effectively performed with local anesthesia, thus increasing access to care and allowing treatment to be made available to a larger population of patients.

• Patient Stratification and Personalized Medicine: The future of surgical treatment for BPH more and more encompasses individualized treatment strategies according to specific patient parameters, prostate anatomy, and the severity of symptoms. With improved diagnostics and imaging, patient stratification becomes more effective, resulting in more individualized treatment strategies. This solution is designed to maximize outcomes, reduce complications, and enhance patient satisfaction by choosing the best surgical modality for each case, rather than adopting a one-size-fits-all mentality.

• Artificial Intelligence and Robotics Integration: Though still in the early days for everyday BPH surgery, artificial intelligence (AI) and robotics will have an increasingly important role. AI can be used to assist with surgical planning, image interpretation, and even possibly real-time intraoperative guidance, increasing accuracy and safety. Robotic systems, already proven in other urologic procedures, are being investigated for BPH and present potential advantages in difficult cases or for learning situations, leading to enhanced operating skills and uniformity. These new trends combined are individually transforming the benign prostatic hyperplasia surgical treatment market with an acceptance of less invasive, more personalized, and technologically advanced treatments. A focus on better patient outcomes, shorter recovery periods, and cost savings is spurring the innovation and implementation. This transformation holds promise for a future in which BPH is managed more effectively, more accessible, and more highly individualized to meet the needs of individual patients, ultimately maximizing the quality of life for millions of those suffering from this prevalent condition.

Recent Development in the Benign Prostatic Hyperplasia Surgical Treatment Market

The benign prostatic hyperplasia surgical treatment market is in a state of perpetual movement, spurred by ongoing innovation in the quest for better patient outcomes, less invasiveness, and quicker recovery. Recent trends demonstrate a coalescing effort toward progressing beyond conventional, more time-consuming procedures, adopting technologies that provide a faster return to normal life and lower complications. These developments are not incremental improvements but reflect important shifts in the management of BPH worldwide. This introduction will point out five major recent innovations that are greatly affecting the landscape of surgical treatment for BPH.

• Mass Adoption of Water Vapor Thermal Therapy: Reum, a minimally invasive treatment with heated water vapor, has attracted strong support for its efficacy in lowering prostate volume and enhancing urinary symptoms with an excellent safety profile. Being able to be delivered in an office setting under local anesthesia has popularized it with patients and doctors alike, leading to the swift adoption in all types of healthcare systems. This has broadened treatment choices for those looking for less invasive alternatives to medication or more extensive surgery.

• Prostatic Urethral Lift Indications and Usage Expansion: The Uro Lift system continues to be increasingly used, with increased clinical evidence of long-term benefit and maintenance of sexual function. Recent developments involve widened indications for use in patients with different prostate sizes and anatomies. The ease of use and lack of invasiveness of Uro Lift are the reasons why many patients find it appealing, thus fueling growing market penetration and cementing its status as a mainstream treatment for BPH.

• Refinements in Holmium Laser Enucleation of the Prostate Techniques: Ho LEP is still a gold standard for larger prostates, and newer developments are centered around optimizing techniques, enhancing instrumentation, and augmenting surgeon expertise. This involves the creation of higher-powered lasers and more advanced morcellators, resulting in enhanced efficiency and speed of tissue removal. Such advancements add to the safety and efficacy of Ho LEP and solidify its position as a gold standard for the definitive surgical treatment of impactful BPH.

• Newer Transurethral Ablation Technologies: In addition to Reum, newer transurethral ablation technologies are in development, providing additional minimally invasive options. These include several types of prostatic artery embolization (PAE), which entails interrupting blood flow to the prostate to reduce its size. Although some remain in development or have limited uptake, their creation continues to drive the trend towards non-incisional and less-invasive alternatives, providing an increasing array of options for both patients and physicians.

• Greater Emphasis on Post-Procedure Patient Quality of Life and Functional Outcomes: New developments are not only concerned with efficacy but also with enhancing patients’ overall post-procedure quality of life, such as the preservation of sexual and ejaculatory function. This focus has resulted in the creation and evolution of procedures that are specifically intended to reduce side effects routinely seen with conventional BPH procedures. This patient-focused strategy is pushing innovation toward therapies that provide not only symptom remission but also preserve key elements of male health. These new advancements as a whole are influencing the surgical treatment market for benign prostatic hyperplasia by inducing a paradigm shift towards minimally invasive, more patient-centric, and function-conserving procedures. Increased availability and utilization of MISTs, combined with the continuous optimization of established laser treatments, are offering an expanded spectrum of effective and safer options of treatment. This transformation is resulting in enhanced patient satisfaction, reduced recovery periods, and a more diversified market, ultimately optimizing BPH management.

Strategic Growth Opportunities in the Benign Prostatic Hyperplasia Surgical Treatment Market

The benign prostatic hyperplasia surgical treatment market will witness substantial strategic growth on the back of a growing global elderly population, rising awareness of treatment, and ongoing technological advancements in surgical methods. Determining and leveraging certain growth opportunities through different applications is fundamental for business players to increase their market share and address changing patient demands. These possibilities tend to exist in areas that provide enhanced patient outcomes, lower invasiveness, and cost savings. This introduction will discuss five major growth opportunities in the BPH surgical treatment market based on particular application areas.

• Growth in Outpatient and Office-Based Procedures: One key growth possibility exists in the further development and use of BPH treatments that are available for outpatient or office procedures. This decreases healthcare expense, enhances patient convenience, and reduces the risk of hospital-acquired infection. Devices such as Uro Lift and Reum are a great example of this direction. Putting money into training urologists in performing these procedures outside the conventional operating room, along with designing more such devices, will unleash massive market expansion by increasing accessibility.

• Treating Younger Patients with BPH in Its Early Stages: Although BPH is common in older men, there is a new opportunity to treat younger patients with early-stage symptoms. These individuals tend to seek procedures that minimize sexual dysfunction and have little downtime. Creating and selling less invasive procedures specifically designed for this population, keeping symptoms at bay while preserving quality of life, is an unexploited market segment with high growth potential, as the disease can be halted by early treatment.

• Treating Large Prostate Glands with More Advanced Laser Technology: While MISTs are getting more attention, a large share of BPH patients have large prostate glands that still need more definitive surgery. Improvements in laser technologies, more importantly, Holmium Laser Enucleation of the Prostate (Ho LEP) and other high-power lasers, represent a strategic growth potential. Continued innovation within these spaces, such as enhanced instrumentation and training, can make these treatments the superior choice to open or robot-assisted surgery for big prostates.

• Expansion in Emerging Markets with Rising Healthcare Availability: Nations such as China, India, and portions of Southeast Asia offer enormous expansion prospects owing to their big and aging populations, along with enhanced healthcare infrastructure and growing disposable incomes. Strategic investment in these markets, such as localized production, modified pricing methodologies, and extensive physician training, can greatly increase the availability of BPH surgical procedures and access to a gigantic, under-penetrated patient universe.

• Combination Therapies and Personalized Strategies: There is a growth opportunity in creating and marketing combination therapies that combine various modalities for better results, or highly individualized treatment algorithms based on the characteristics of a given patient. For example, adding medical therapy to a minimally invasive procedure, or individualizing surgical selection by prostate volume, symptom degree, and patient preference, is an advanced BPH management strategy that can propel the market by delivering better, more tailored solutions. These strategic growth areas are set to have a significant influence on the benign prostatic hyperplasia surgical treatment market by driving innovation, growing patient access, and maximizing treatment outcomes. Through concentrating on outpatient procedures, targeting particular patient segments, improving laser technologies, entering new emerging markets, and adopting personalized medicine, the market can make significant growth and more adequately address the differing needs of the worldwide BPH patient population, translating into more effective and efficient care.

Benign Prostatic Hyperplasia Surgical Treatment Market Driver and Challenges

The benign prostatic hyperplasia surgical treatment market is influenced by a complex interplay of diverse technological, economic, and regulatory drivers. These drivers are both strong drivers of growth and strong barriers to advancement. Knowing these drivers and challenges is paramount for the stakeholders to effectively strategize, create innovative solutions, and traverse the complicated BPH management landscape. From the rising demand for less-invasive treatments to reimbursement complexities and regulatory approvals, these forces determine the direction of the market and impact new therapy adoption. The factors responsible for driving the benign prostatic hyperplasia surgical treatment market include: 1. Aging Global Population: The most important force is the ever-growing older male population globally. Prevalence of BPH rises with age, guaranteeing an expanding pool of patients in need of treatment. With increasing life expectancy in industrialized and developing economies, the number of men suffering from symptoms of BPH will keep growing, propelling long-term demand for both existing and new surgical treatments, forming a cornerstone demographic driver for market expansion. 2. Growing Demand for Minimally Invasive Treatments: Patients and physicians increasingly prefer minimally invasive surgical therapies (MIST) compared to conventional open surgery because of less pain, shorter hospital stay, quicker recovery, and fewer complications. This high preference is fueling research, development, and implementation of advanced BPH treatments such as Uro Lift and Reum, driving strong market growth in this area through providing enhanced patient experiences. 3. Technological Developments in Surgical Methods and Equipment: Continual advancement in surgical instruments, imaging, and energy delivery devices is a key driver. Advances in laser technologies (Ho LEP), robot-assisted surgery, and new methods of ablation are enhancing the efficacy, safety, and accuracy of BPH surgery. The new technology increases the scope for conditions that can be treated and enhances results, rendering surgical procedures more desirable and feasible for patients. 4. Increasing Healthcare Spend and Awareness: Across the world, growing healthcare spend, most notably in developing economies, is enhancing access to upmarket BPH treatment. At the same time, increased public campaigns and improved education among physicians are contributing to early diagnosis and an increased patient inclination towards seeking surgical relief for BPH symptoms, instead of tolerating the discomfort or being solely dependent on medical management. 5. Positive Reimbursement Policies and Clinical Guidelines: Government and private payers’ positive reimbursement policies, particularly for new minimally invasive procedures, play a vital role in their adoption in the market. Furthermore, changing urological associations’ clinical guidelines that support and recommend these advanced technology-based techniques are a key driver for their universal use, making optimal treatments accessible and affordable. Challenges in the benign prostatic hyperplasia surgical treatment market are: 1. Higher Cost of New Technologies: Although they are better, several new, more advanced BPH surgical technologies have a greater initial capital expense for facilities and a greater cost per procedure. This can be an obstacle to adoption, especially in financially constrained healthcare systems or less developed nations, curtailing the widespread use of these new treatments and hindering market penetration. 2. Limited Awareness and Training in Emerging Markets: Although awareness is increasing, in most developing countries, the general public remains largely unaware of contemporary BPH surgical techniques, and trained urologists familiar with cutting-edge minimally invasive surgery are in short supply. Limited knowledge and skills prevent the introduction of newer treatments, with older, more conventional treatments remaining the mainstay. 3. Approval Process and Regulatory Barriers: The strict and frequently long regulatory approval process for innovative medical devices and procedures can deter market entry and drive up development costs. Getting approvals from organizations such as the FDA in the US, NMPA in China, or EMA in Europe involves huge clinical tests and information, which can be a serious challenge for businesses hoping to launch innovative BPH treatments. The dynamic interaction of these drivers and challenges is transforming and influencing the benign prostatic hyperplasia surgical treatment market. Though the aging population, patient preference for minimally invasive procedures, and technological advancements are driving immense growth, the exorbitant cost of new technology, limited awareness in some geographies, and complicated regulatory environments present significant barriers. Overcoming these impediments while harnessing the drivers will be critical to enabling companies to succeed and make a positive impact on BPH management worldwide.

List of Benign Prostatic Hyperplasia Surgical Treatment Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies benign prostatic hyperplasia surgical treatment companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the benign prostatic hyperplasia surgical treatment companies profiled in this report include-

• Alembic Pharmaceuticals

• Asahi Kasei Corporation

• Boston Scientific Corporation

• Cleveland Clinic

• Coloplast Group

• Cook Medical

• Karl Storz

• Medifocus

• Medtronic

• Olympus Corporation

Benign Prostatic Hyperplasia Surgical Treatment Market by Segment

The study includes a forecast for the global benign prostatic hyperplasia surgical treatment market by type, end use, and region.

Benign Prostatic Hyperplasia Surgical Treatment Market by Type [Value from 2019 to 2031]:

• Transurethral Resection of the Prostate

• Prostatic Urethral Lift

• Water Vapor Therapy

• Laser Therapy

• Aquablation Therapy

• Transurethral Microwave Thermotherapy

• Others

Benign Prostatic Hyperplasia Surgical Treatment Market by End Use [Value from 2019 to 2031]:

• Hospitals

• Ambulatory Surgery Centers & Clinics

• Homecare Settings

Benign Prostatic Hyperplasia Surgical Treatment Market by Region [Value from 2019 to 2031]:

• North America

• Europe

• Asia Pacific

• The Rest of the World

Country Wise Outlook for the Benign Prostatic Hyperplasia Surgical Treatment Market

The worldwide market for benign prostatic hyperplasia surgical treatment is in the midst of tremendous change, fueled by the revolution in minimally invasive surgical procedures, better patient outcomes, and changing healthcare policies. This fast-paced market is experiencing a transition towards less invasive surgeries from conventional open surgery, with faster recovery and fewer complications. The rising incidence of BPH in an increasingly aging male population globally further spurs innovation and the use of newer treatment options. This introduction will offer a brief overview of recent advances in leading geographical markets: the United States, China, Germany, India, and Japan, each with its distinctive contributions and market profile.

• United States: The US BPH surgical treatment market is marked by quick take-up of innovative, minimally invasive surgical treatments (MISTs). They include prostatic urethral lift (PUL) devices such as Uro Lift and more recent water vapor thermal therapy (Reum). There is a focus on outpatient surgery, shorter hospital stays, and enhanced patient quality of life. The reimbursement policies have an immense effect on the adoption of such advanced technologies, with constant attempts to extend coverage to new, effective therapies. The market also witnesses ongoing research into even less invasive, office-based technologies.

• China: The Chinese surgical treatment market for BPH is growing significantly, driven by its huge and aging population, and rising access to high-end medical technologies. Whereas conventional TURP is still dominant, there is a rising demand for and use of laser-based treatments (e.g., Ho LEP) and other minimally invasive procedures. Government support for increasing healthcare infrastructure and making healthcare more affordable is driving market growth. Local industry players are also surfacing, enhancing competitiveness and greater access to treatments.

• Germany: Germany is a developed European market for BPH surgical therapies with high healthcare standards and tech adoption. Although TURP is still a go-to, there is a strong trend towards the use of laser enucleation methods (such as Ho LEP) because of their effectiveness for bigger prostates and good results. Germany also demonstrates a consistent adoption of MISTs, prompted by clinical evidence and patient preference towards less invasive procedures. It is all about long-term efficacy, safety, and effective healthcare resource utilization within a well-established health system.

• India: The Indian BPH surgical treatment market is going through a substantial transformation, characterized by rising awareness, enhanced healthcare infrastructure, and growing disposable incomes. Although older-fashioned TURP continues to be prevalent, rising demand for newer laser-based procedures (such as Ho LEP and Green Light laser) is being met in urban hospitals and private facilities. Economics is still a determining factor in treatment options. The market is also witnessing the incremental roll-out of newer MISTs, with potential for broad acceptance based on improving access and awareness across the country’s diversified healthcare landscape.

• Japan: The Japanese BPH surgical treatment market is marked by an aging population and a strong focus on precision medicine and new technology. Though traditional surgery is still used, there is a high adoption of laser vaporization and enucleation procedures (e.g., Ho LEP) because of their high efficacy and good safety profiles. Japanese health care providers are also investigating and incorporating newer minimally invasive alternatives, focusing on patient comfort, rapid recovery, and retention of sexual function. Research and development in new BPH treatments continue to be a priority.

Features of the Global Benign Prostatic Hyperplasia Surgical Treatment Market

Market Size Estimates: Benign prostatic hyperplasia surgical treatment market size estimation in terms of value ($B). Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions. Segmentation Analysis: Benign prostatic hyperplasia surgical treatment market size by type, end use, and region in terms of value ($B). Regional Analysis: Benign prostatic hyperplasia surgical treatment market breakdown by North America, Europe, Asia Pacific, and Rest of the World. Growth Opportunities: Analysis of growth opportunities in different types, end uses, and regions for the benign prostatic hyperplasia surgical treatment market. Strategic Analysis: This includes M&A, new product development, and competitive landscape of the benign prostatic hyperplasia surgical treatment market. Analysis of competitive intensity of the industry based on Porter’s Five Forces model.

FAQ

Q1. What is the growth forecast for benign prostatic hyperplasia surgical treatment market? Answer: The global benign prostatic hyperplasia surgical treatment market is expected to grow with a CAGR of 5.2% from 2025 to 2031. Q2. What are the major drivers influencing the growth of the benign prostatic hyperplasia surgical treatment market? Answer: The major drivers for this market are the rising geriatric male population, the growing awareness of treatment options, and the increase in prostate-related disorders. Q3. What are the major segments for benign prostatic hyperplasia surgical treatment market? Answer: The future of the benign prostatic hyperplasia surgical treatment market looks promising with opportunities in the hospital, ambulatory surgery centers & clinic, and homecare setting markets. Q4. Who are the key benign prostatic hyperplasia surgical treatment market companies? Answer: Some of the key benign prostatic hyperplasia surgical treatment companies are as follows:

• Alembic Pharmaceuticals

• Asahi Kasei Corporation

• Boston Scientific Corporation

• Cleveland Clinic

• Coloplast Group

• Cook Medical

• Karl Storz

• Medifocus

• Medtronic

• Olympus Corporation Q5. Which benign prostatic hyperplasia surgical treatment market segment will be the largest in future? Answer: Lucintel forecasts that, within the type category, transurethral resection of the prostate is expected to witness the highest growth over the forecast period. Q6. In benign prostatic hyperplasia surgical treatment market, which region is expected to be the largest in next 5 years? Answer: In terms of region, North America is expected to witness the highest growth over the forecast period. Q7. Do we receive customization in this report? Answer: Yes, Lucintel provides 10% customization without any additional cost.